Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer
Brief Summary: To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients with advanced stomach and oesophageal cancer.


Options:
A: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 3mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386 10mg/kg, Drug: Cisplatin, Drug: Capecitabine | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386 placebo, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: AMG 386 placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: AMG 386 10mg/kg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: AMG 386 3mg/kg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): B
B: Arm Label: Phase 2 Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: Cisplatin, Drug: Placebo | Arm Label: Phase 1b; Type: OTHER; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Arm Label: Phase 2 Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Epirubicin, Drug: AMG 102, Drug: Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: AMG 102; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 1b, Phase 2 Arm A, Phase 2 Arm B, Phase 2 Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2 Arm C
C: Arm Label: Arm A EOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: epirubicin, oxaliplatin, capecitabine (EOX) | Arm Label: Arm B EOX + panitumumab.; Type: ACTIVE_COMPARATOR; Interventions: Drug: EOX + panitumumab | Intervention Type: DRUG; Name: epirubicin, oxaliplatin, capecitabine (EOX); Assigned to Arm(s): Arm A EOX | Intervention Type: DRUG; Name: EOX + panitumumab; Assigned to Arm(s): Arm B EOX + panitumumab.
D: Arm Label: Rilotumumab; Type: EXPERIMENTAL; Interventions: Drug: Rilotumumab, Drug: Epirubicin, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Epirubicin, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Rilotumumab; Assigned to Arm(s): Rilotumumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Placebo, Rilotumumab | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Placebo, Rilotumumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Placebo, Rilotumumab

Answer: C